Immunology

Inflammatory bowel disease (#IBD) is a complex condition that can have a profound impact on a person’s mental and physical well-being. To learn more about the importance of optimal disease management, explore our excerpt in the October edition of the European Federation of Crohn's and Ulcerative Colitis Associations magazine: https://bit.ly/4eLrFP5

NEWS: New post-hoc data of #atopicdermatitis stratified by the severity of disease in the head and neck region was presented today at the #EADVCongress. Learn more about how we’re striving to meet patient needs through new research and data in immune-mediated skin diseases: https://bit.ly/3zteu6r [Video description: On-screen text reads, “Immunology News.”]

Tune into this year’s #EADVCongress to see how we’re striving to meet patient needs through new research and data in immune-mediated skin diseases: https://bit.ly/47Gie0P [Video description: Animation of people, a person speaking at a podium, and Amsterdam on a map. On-screen text reads, “EADV 2024 Looking ahead. 33 accepted abstracts across 5 immune-mediated skin diseases, atopic dermatitis, psoriasis, psoriatic arthritis, vitiligo, hidradenitis suppurativa, 6 oral presentations, 3 symposia. See you there!”]

#Eczema is a chronic, inflammatory condition caused by several factors, including an overactive immune system. This disease can impact one’s life physically and emotionally, beyond dry skin and itch. This upcoming #AtopicEczemaDay, we’re committed to empowering those that live with?eczema to have honest conversations with their dermatologist. Learn more: https://bit.ly/3znj7Pb [Image description: On-screen text reads: “Over 200 million people globally live with atopic eczema, making it one of the most prevalent immune-mediated skin diseases on the planet.” Followed by a quote from Yolanda Armendariz, Senior Director, Therapeutic Area Lead, Dermatology, Medical Affairs & HEOR, Global Therapeutics, AbbVie, “In collaboration with the dermatology community, we work every day for people living with atopic eczema so they can live confidently in their skin.”]

We’re striving to make a difference for people impacted by #IBD. Learn how we’re working to reimagine the standards of care through innovation and research: https://abbv.ie/cb1af7 #UlcerativeColitis #CrohnsDisease [Image description: Roopal Thakkar, M.D., EVP, R&D, Chief Scientific Officer, AbbVie, says, "We are committed to strengthening our diversified inflammatory bowel disease (IBD) portfolio, providing healthcare professionals with more options to treat their IBD patients."]

JUST IN: The European Medicines Agency approved our latest treatment for adults with moderately to severely active #UlcerativeColitis. Read more: https://bit.ly/3SpMKWF #IBD [Video description: On-screen text reads, “Immunology News. European Commission Approval in Ulcerative Colitis.”]

Celsius Therapeutics is now part of AbbVie. This #acquisition expands our pipeline with a novel approach in #IBD – because fueling scientific progress takes all of us. Learn more: https://bit.ly/3XI7w7d $ABBV [Video description: On-screen text reads, “Celsius is now part of AbbVie” followed by the AbbVie and Celsius logos.]

Reflecting on the data we presented at #EULAR2024, we remain dedicated to addressing some of the most difficult-to-treat rheumatic diseases to make a difference in patients' lives. Explore: https://bit.ly/3xh7xUU #Rheumatology [Video description: Tim Shaw, Therapeutic Area Head, Rheumatology, International Medical Affairs, AbbVie, says, “Congresses like EULAR enable us to engage with the rheumatology community and work together toward a common goal of improving life for patients living with rheumatic diseases.”]